YT 001
Alternative Names: YT-001Latest Information Update: 04 Dec 2024
Price :
$50 *
At a glance
- Originator Excyte Biopharma
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 04 Oct 2024 Early research in Non-Hodgkin's lymphoma in China (Parenteral) prior to October 2024 (Excyte Biopharma pipeline, October 2024)
- 04 Oct 2024 Early research in Precursor cell lymphoblastic leukaemia-lymphoma in China (Parenteral) prior to October 2024 (Excyte Biopharma pipeline, October 2024)